Omeros (OMER) announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for ...

Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

Omeros announces positive results from a pivotal narsoplimab trial in TA-TMA, showing significant survival benefits and ...

Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...

During his doctoral research, Umakhanth investigated the protein-protein interactions leading to the lectin pathway of complement activation, an important component of innate immune system. His ...

Omeros reports that narsoplimab has not raised any notable safety issues across all clinical studies. For the treatment of TA ...

Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic ...